Novo Nordisk Says New Obesity Drug Helps Patients Lose Weight in Mid-Stage Trial

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.

Weight-Loss Drugs Don’t Appear to Work Against Alzheimer’s

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

5 things to know about the new obesity pills that are on the way

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.